Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Enrolling By Invitation
18 years - 65 years
All
Phase
3
100 participants needed
1 Location
Brief description of study
This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Alopecia Areata,Alopecia
-
Age: 18 years - 65 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 849929
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
